MXPA04004658A - Anticuerpos monoclonales especificos para tumores. - Google Patents

Anticuerpos monoclonales especificos para tumores.

Info

Publication number
MXPA04004658A
MXPA04004658A MXPA04004658A MXPA04004658A MXPA04004658A MX PA04004658 A MXPA04004658 A MX PA04004658A MX PA04004658 A MXPA04004658 A MX PA04004658A MX PA04004658 A MXPA04004658 A MX PA04004658A MX PA04004658 A MXPA04004658 A MX PA04004658A
Authority
MX
Mexico
Prior art keywords
monoclonal antibodies
tumor
human monoclonal
specific
monoclonal antibody
Prior art date
Application number
MXPA04004658A
Other languages
English (en)
Inventor
D Watkins Jeffry
Original Assignee
Applied Molecular Evolution
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Molecular Evolution filed Critical Applied Molecular Evolution
Publication of MXPA04004658A publication Critical patent/MXPA04004658A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Abstract

La invencion ofrece anticuerpos monoclonales y fragmentos funcionales humanos especificos para tumores. Se proporcionan tambien acidos nucleicos que codifican anticuerpos monoclonales y fragmentos funcionales humanos especificos para tumores. Se proporciona tambien un metodo para reducir la proliferacion de celulas neoplasticas. El metodo consiste en la administracion de una cantidad efectiva de anticuerpo monoclonal humano o fragmento funcional especifico para tumor. Se proporciona tambien un metodo para detectar una celula neoplastica en una muestra. El metodo consiste en la puesta en contacto de una celula con un anticuerpo monoclonal o fragmento funcional especifico para tumor y la deteccion del enlace especifico del anticuerpo monoclonal o fragmento funcional con la muestra.
MXPA04004658A 2001-11-19 2002-11-19 Anticuerpos monoclonales especificos para tumores. MXPA04004658A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98990101A 2001-11-19 2001-11-19
PCT/US2002/037134 WO2003044036A1 (en) 2001-11-19 2002-11-19 Tumor specific monoclonal antibodies

Publications (1)

Publication Number Publication Date
MXPA04004658A true MXPA04004658A (es) 2004-08-13

Family

ID=25535569

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004658A MXPA04004658A (es) 2001-11-19 2002-11-19 Anticuerpos monoclonales especificos para tumores.

Country Status (8)

Country Link
EP (1) EP1446416A4 (es)
JP (1) JP2005517388A (es)
CN (1) CN1615315A (es)
AU (1) AU2002365978A1 (es)
BR (1) BR0214288A (es)
CA (1) CA2467020A1 (es)
MX (1) MXPA04004658A (es)
WO (1) WO2003044036A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009012891A (es) * 2007-05-31 2009-12-10 Merck & Co Inc Proteinas de union a antigeno dirigidas a staphylococcus aureus orf0657n.
LT2710033T (lt) 2011-05-17 2021-06-10 The Rockefeller University Žmogaus imunodeficito virusą neutralizuojantys antikūnai ir jų panaudojimo būdai
MX2020010913A (es) 2018-04-17 2021-01-08 Celldex Therapeutics Inc Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281335B1 (en) * 1993-10-08 2001-08-28 Coulter Corporation Hybridoma and anti-KC-4 humanized monoclonal antibody
PT859841E (pt) * 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
BR9710811A (pt) * 1996-05-22 1999-08-17 Novopharm Biotech Inc Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
US6303323B1 (en) * 1997-10-21 2001-10-16 Cancer Research Campaign Technology Limited Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies
US6787638B1 (en) * 1998-12-02 2004-09-07 Applied Molecular Evolution, Inc. Tumor specific human monoclonal antibodies and methods of use
IT1307864B1 (it) * 1999-04-20 2001-11-19 Istituto Naz Per La Ricerca Su Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di

Also Published As

Publication number Publication date
EP1446416A4 (en) 2005-11-30
WO2003044036A1 (en) 2003-05-30
JP2005517388A (ja) 2005-06-16
CN1615315A (zh) 2005-05-11
CA2467020A1 (en) 2003-05-30
EP1446416A1 (en) 2004-08-18
AU2002365978A1 (en) 2003-06-10
BR0214288A (pt) 2004-11-09

Similar Documents

Publication Publication Date Title
ATE229035T1 (de) Modifiziertes radio-antikörper fragment zur reduzierten renalen aufnahme
IL200404A (en) Couplings of 191p4d12 (b) protein-binding antibodies and their use in the treatment of cancer
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
IL126314A (en) Monoclonal antibodies having an antigen binding region specific for the extracellular domain of prostate specific membrane antigen (psma)
BG112042A (bg) Човешки антитела, свързващи човешки тумор некрос фактор- ? (tnf-?)
TW200635946A (en) Binding proteins specific for human matriptase
BG111337A (bg) Човешки антитела, които свързват човешки il-12 и методи за получаване
PL350318A1 (en) Protein isolation and analysis
IL210392A0 (en) Antibodies that bind to tgf-?? binding proteins with an affinity of 106m-1 and uses thereof
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
EP1383785A4 (en) RECOMBINANT, TUMOR-SPECIFIC ANTIBODIES AND THEIR USE
CY1109645T1 (el) Ανθρωπινος πρωτεϊνικος υποδοχεας τυπου toll, σχετικα αντιδραστηρια και μεθοδοι
WO2000032635A3 (en) Tumor specific human monoclonal antibodies and methods of use
IL139700A0 (en) Immunotherapeutic composition and method for the treatment of prostate cancer
DE69626423D1 (de) Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
EP1605266A4 (en) TUMOR MARKER OF UROTHELIAL CARCINOMAS
DE69622259T2 (de) Cd40 bindendes protein zur stimulierung der immunantwort
EP1411962A4 (en) MONOCLONAL ANTIBODY TREATMENT OF PANCREATIC CANCER
MXPA04004658A (es) Anticuerpos monoclonales especificos para tumores.
AU3556901A (en) Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
EP1506401A4 (en) METHOD FOR THE ANALYSIS OF PROCEDYME FORMS OF A PROSTATE-SPECIFIC ANTIGEN IN SERUM FOR IMPROVING THE PROSTATE ACID DETECTION PROCEDURE
ATE481644T1 (de) Prognose des verlaufs einer krebserkrankung
EP1593691A4 (en) PROCESS OF OBTAINING HUMAN MONOCLONAL ANTIBODIES FOR INHIBITING THE DISTRACTION OF CANCER CELLS
DE59907958D1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
AU2003225900A1 (en) Antibody disulfide isomers, use thereof, and methods of analyzing same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal